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I N T R O D U C T I O N
Anemia is a common complication among patients with latestage chronic kidney disease (CKD) and is associated with risk of renal progression, left ventricular hypertrophy and systolic dysfunction, leading to increased risk for hospitalization, hospital length of stay, impaired quality of life and significantly reduced patient survival [1, 2] . Iron supplementation and erythropoiesis-stimulating agent (ESA) are current treatment options for correcting anemia and avoiding the needs for red cell transfusion. While prospective randomized trials have shown that correction of renal anemia by ESA treatment is associated with improvement in quality of life, it cannot improve left ventricular hypertrophy or cardiac and renal prognosis, and increases risks for serious events in predialysis patients [3, 4] . On the basis of these results, the US Food and Drug Administration (FDA) recently advocated for more conservative treatment of anemia in CKD patients, i.e. using the lowest possible ESA dose required to reduce the need for transfusions [5] . The controversies are whether the harm stemmed from the normalization of the hemoglobin level itself or from ESA dosing. Taking into account the adverse reactions to ESA (hypertension, seizure, vascular access thrombosis), newer strategies for correcting anemia are awaited.
Indoxyl sulfate (IS) is a representative protein-bound uremic toxins accumulated in renal patients. It was proposed that this solute contributes to the development of renal fibrosis, endothelial dysfunction and cell senescence by inducing complex redox alteration in renal tubular, mesangial and vascular smooth muscle cells and by suppressing Klotho expression via alteration of DNA methylation [6] [7] [8] . High serum IS and p-cresyl sulfate (PCS) levels were associated with renal progression and mortality in CKD patients [9, 10] . In addition, IS suppressed erythropoietin (EPO) mRNA expression, reduced plasma EPO levels via disturbance in oxygen-sensing mechanism [11] and attenuated EPO-induced tyrosine phosphorylation of EPO receptor leading to EPO resistance [12] . The oral adsorbent AST-120 reduced IS levels and had antioxidant and renoprotective properties [13, 14] . A hypothetical therapeutic approach to CKD-related anemia is to improve EPO activity by reducing accumulated toxins with oral adsorbents. However, this hypothesis has not been proven clinically in a randomized manner to date.
We conducted a randomized, crossover, fixed dose, openlabel, controlled trial to investigate the efficacy of an oral adsorbent of uremic toxins, AST-120, in renal function and anemia of CKD patients. The aim of the present study was to evaluate the effect of add-on AST-120 therapy on the change in renal function and serum hemoglobin levels among Stage 5 CKD patients receiving conventional ESA treatment for CKD-related anemia.
M AT E R I A L S A N D M E T H O D S

Patient selection
Patients who visited the outpatient clinics of Chang Gung Memorial Hospital at Keelung, had CKD Stage 5,  were not yet on dialysis [estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m 2 , determined by the abbreviated modification of diet in renal disease (MDRD) equation in two separate measurements within a 3-month interval], aged 18-80 years, were ESA-naïve, had hemoglobin <10 g/dL and adequate iron storage (serum ferritin > 200 ng/dL or transferrin saturation > 20%) were eligible for enrollment. Patients were excluded from the study if any one of the following condition is present: liver cirrhosis, bone marrow disorder, blood pressure >170/80 mmHg on three occasions, recent cardiovascular disease (coronary artery disease, myocardial ischemia, cerebrovascular disease or peripheral artery disease) in past 3 months, acute tubular necrosis in the past 3 months, gastrointestinal bleeding in the past 3 months, malignancy, history of renal transplantation and graft failure or unwillingness to participate in the trial.
Study design, protocol and end points Over a 4-week screening period, 62 patients were recruited for laboratory assessments. Fifty-one patients were eligible and provided their informed consent. The study adopted a randomized, open-label, crossover, controlled, single center and fixed dose design. Eligible patients were randomly assigned to two groups, using a random table in a 1:1 ratio to begin the 12-week intervention period [6 g per day of AST-120 with once-monthly administration of continuous EPO receptor activator (CERA), Treatment A] followed by a control period (once-monthly administration of CERA alone, Treatment B) by using the sequence AB, for the AST-120 first group, or vice versa (sequence BA, AST-120 later group) with a 4-week washout period in between. AST-120 was given in sachet containing powder of black spherical particles (2 g/sachet). Enrolled patients received CERA, methoxy polyethylene glycol-epoetin beta (MIRCERA, Roche), at a starting dose of 1.2 μg/kg subcutaneous Q4W. Doses of CERA were adjusted in both arms of treatment to maintain within 1 g/dL of the response hemoglobin value and in the range of 10-12 g/dL by implementing a 25% dose increase or decrease, and interrupted if hemoglobin levels exceeded 12 g/dL. Administration of CERA was permitted during the washout period. Iron therapy was not allowed since the study had included patients with adequate iron storage. This study was conducted in adherence to the Declaration of Helsinki and was approved by the Ethics Committee of the Institutional Review Board at Chang Gung Memorial Hospital (Clinical Trials.gov NCT01681303).
Patients were seen monthly. A monthly amount of the study drug was delivered at each visit after patients returned the empty drug container received at the last visit. Compliance was monitored by counts of the returned containers. At each visit, vital signs, adverse events, hospitalization, transfusions and concomitant medications were recorded. The primary end point was the mean change from baseline serum creatinine (Scr) levels or mean eGFR following add-on AST-120. The secondary end point of the study involved detecting the mean change from the baseline hemoglobin level following add-on AST-120 with conventional CERA treatment. The main outcome variables, namely hemoglobin, Scr, serum total and free forms of IS and PCS and ferritin were measured at baseline (0 months) and 3 (end of Period 1), 4 (after washout period) and 7 months (end of Period 2), respectively. Withdrawal criteria were development of symptomatic anemia requiring blood component transfusion, initiation of dialysis therapy, any major cardiovascular event, any intolerable drugs reaction or refusal of patient to continue with the study.
Biochemical measurements
Scr was assessed by spectrophotometric analysis using a modified kinetic Jaffe reaction. Serum PCS and IS (free and protein-bound fractions) were analyzed with liquid chromatography tandem mass spectrometry (LC-MS, API4000Q-TRAP, Applied Biosystems). In summary, serum samples were prepared and deproteinized by organic solvent denaturation. The free concentrations of IS and PCS were measured in serum ultrafiltrates, obtained by using Amicon Ultra 30 K filter (centrifuge 10 000 r.p.m for 30 min), followed by the same sample preparation and analysis that was performed for serum PCS and IS. High-performance liquid chromatography was performed at room temperature using a dC18 column (3.0 × 50 mm). The buffers used were (A) 0.1% formic acid and (B) 1 mM NH 4 OAc + 0.1% formic acid in 100% acetonitrile. The flow rate was 0.6 mL/min with a 3.5-min gradient cycling from 90% A/10% B to 10% A/90% B. Under these conditions, PCS and IS were eluted at 2.73 and 2.48 min, respectively. Standard curves for PCS and IS were constructed at 1, 5, 10, 50, 250, 500 and 1000 μg/L; both were processed in the same manner as the serum samples, correlating with the serum samples with average r 2 values of 0.996 ± 0.003. Quantitative results were obtained and calculated in terms of their concentrations (μg/mL). The sensitivity of this assay was 1 μg/mL for PCS and 1 μg/mL for IS.
Statistical methods
Both phases were designed as an AB/BA crossover trial. Using a two-sided paired t-test at α-error probability of 10% and assuming an effect size of 0.5 between the pretreatment and posttreatment measurements, 18 subjects per sequence (for a total of 36 patients) were required to provide 90% power to detect difference. Descriptive statistics were expressed as the mean ± standard deviation, median (range) and/or frequency ( percentage) where appropriate. All numerical variables were tested for normality using the Kolmogorov-Smirnov test. Data were log-transformed to approximate the normal distribution with right skewness. Patients in two sequences were compared in terms of baseline characteristics using Student's t-test or the Mann-Whitney U-test for continuous variables and Fisher exact test for dichotomous variables. The Wilcoxon signedrank test was used to compare the change from baseline between treatment regimens and to assess change from baseline within each treatment. The outcome of end points were analyzed with mixed-effects model of variance, which included sequence, treatment and period as fixed effect and subjects nested within sequence as a random effect. Hierarchical regression approach was used to delineate relationships among changes of IS/PCS, eGFR and hemoglobin levels. All statistical tests were two-tailed, and a P value < 0.05 was considered statistically significant. Data were analyzed using the SPSS 17.0 
R E S U LT S
Fifty-one patients were randomized into this two-period crossover trial and 11 patients discontinued treatment after a few months of enrollment as outlined in Figure 1 . Six patients withdrew from the study due to renal progression to end-stage renal disease (ESRD), and underwent dialysis therapy before the first month of enrollment (four patients in the AST-120 first group and two patients in the AST-120 later group). One patient who was randomized into the AST-120 later group died from cardiovascular disease in the second month after randomization; another patient from the same group refused to continue the study because of urticaria. Three patients from the AST-120 first group withdrew their consent (two patients, due to severe constipation and one due to poor palatability). Therefore, 40 patients completed the study and were included in the per protocol analysis. Table 1 summarizes the baseline characteristics of the study population. Figure 2 depicts the mean change of eGFR towards the end of Period 1 in both treatment arms. Overall, Treatment A resulted in a positive change of eGFR levels in contrast to the decrease of eGFR in the Treatment B group. As shown in Table 2 , add-on AST-120 resulted in a positive change of eGFR at both sequence of study (treatment effect, P = 0.025), regardless of the order in which AST-120 was taken ( period effect, P = 0.467). The effect of add-on AST-120 on the renal function as assessed by change of serum Scr was similar to the change in the eGFR levels (Table 2) . Figure 3 compares percentage of patients achieving hemoglobin level >11 g/dL towards the end of Period 1 in two treatment arms. We used the last hemoglobin value before withdrawal to assess change of hemoglobin levels after treatment in the intention to treat patients. Overall, use of add-on AST-120 resulted in a greater proportion of patients achieving hemoglobin level >11 g/dL than use of CERA alone in both intention to treat and per protocol patients. We found that when AST-120 was given first, the difference of changes between the two treatment modes was greater than when it was taken later, which resulted in a significant period effect (P = 0.001, Table 2 ). Regardless of this phenomenon, add-on AST-120 always resulted in a greater proportion of patients reaching hemoglobin levels >11 g/dL than use of CERA alone (treatment effect, P = 0.039, Table 2 ). Figure 4 illustrates the monthly dose of CERA in per protocol patients. Overall, the monthly dose of CERA did not differ between two treatment modes. The dose of CERA during the wash out period was 24.37 ± 3.8 μg in sequence AB and 39.37 ± 4.4 μg in sequence BA, respectively (P = 0.201). The monthly dose of CERA was more likely to be higher in Period 1 than Period 2, regardless of which treatment was given first. However, the dose of CERA was less when AST-120 was added in Period 1 (65.35 ± 30.71 μg in treatment A versus 89.69 ± 30.61 μg in Treatment B group of Period 1, P < 0.001). The mean baseline and posttreatment serum ferritin levels were 241.5 (362.9) and 241.4 (351.8) ng/dL respectively in Treatment A (P = 0.366) and 248.1 (337.4) and 259.1 (292.1) ng/dL, respectively, in Treatment B (P = 0.105). The mean baseline and posttreatment transferrin saturation were 25.3 ± 6.7 and 25.4 ± 6.6% respectively in Treatment A (P = 0. 761), and as well as 28.4 ± 17.7 and 30.7 ± 17.2%, respectively, in Treatment B (P = 0.173). The consumed dose of AST-120 Mixed-effects model of variance analysis for change in serum creatinine: Treatment effect P = 0.025, period effect P = 0.467, carryover effect P = 0.384; change in eGFR: treatment effect P = 0.029, period effect P = 0.988, carryover effect P = 0.673; change in hemoglobin: treatment effect P = 0.039, period effect P = 0.001, carryover effect P = 0.060. 
O R I G I N A L A R T I C L E
was 4.7 ± 1.0 g/day in sequence AB patients and 4.2 ± 1.3 g/day in sequence BA patients, respectively (P = 0.172). Table 3 demonstrates changes of serum IS and PCS following the use of AST-120. Overall, use of AST-120 significantly reduced both serum total and free IS and PCS levels. We performed hierarchical regression analysis to elucidate relationships among change of serum IS and PCS, eGFR and hemoglobin levels (Table 4) . Serum free IS (B = −1.434, P = 0.006) and free PCS levels (B = −1.6, P < 0.001) predicted significantly eGFR (Model 1). Serum free IS (B = −0.045, P = 0.429) and free PCS (B = 0.2, P = 0.764) were less likely to be associated with hemoglobin levels (Model 2a). However, eGFR was associated with hemoglobin (B = 0.045, P = 0.007). A three-stage hierarchical regression was conducted with hemoglobin levels as dependent variable. The results showed that eGFR was an independent predictor for hemoglobin after adjustment of serum free IS (B = 0.044, P = 0.01, Model 3a), serum free PCS (B = 0.05, P = 0.004, Model 3b) or both serum free IS and PCS levels (B = 0.049, P = 0.005, Model 3c). The hierarchical interaction indicated that change of eGFR might play an intermediate role between serum IS/PCS and improved hemoglobin levels. Table 5 lists the safety reports of all patients. AST-120 was associated with more treatment-related adverse events, predominantly in the gastrointestinal system.
D I S C U S S I O N
In this randomized, open-label, crossover, controlled fixed dose study, we found that use of add-on AST-120 in patients with Stage 5 CKD was associated with improvement in renal function, significant greater increase in hemoglobin levels and decrease in serum IS and PCS levels than the use of CERA alone. This study provided evidence that links the decrease of serum IS and PCS levels following the use of AST-120 with improvement in serum hemoglobin levels in CKD patients. Improvement of eGFR might play a key intermediate role between serum IS/PCS and improved hemoglobin levels. This observation may provide insight into novel therapeutic strategies in the clinical care of anemia for late-stage CKD patients.
Administration of ESA, repletion of iron stores and corrections of other underlying causes of anemia are mainstays for the treatment of CKD-related anemia [15] . Other novel therapeutic approaches include inhibition of GATA binding protein-2, hepcidin modulation, EPO gene therapy, hypoxia inducible factor (HIF) stabilization and peptide-based erythropoietic agents such as peginesatide. Given the potential harmful and pleiotropic effect of large-dose ESA and scarce human experience with exploratory treatment modalities, newer strategies for correcting anemia should be investigated.
The beneficial effect of administration of AST-120, a carbonaceous oral adsorbent that lowers endogenous protein-bound uremic toxins levels [16] , on increased serum hemoglobin levels in our CKD patients confirms and extends the previous observations made in experimental models. In vitro, IS increased oxygen consumption in proximal renal tubules dependent on sodium-potassium adenosine triphosphatase and oxidative stress, decreased renal oxygenation and consequently aggravated hypoxia in the remnant rat kidneys [17] . In animal models, the accumulation of sub-cytotoxic levels of IS resulted in desensitization of the oxygen-sensing mechanism in EPOproducing cells by suppressing EPO mRNA expression due to alteration of the nuclear translocation of subunit-α of HIF and its transcriptional activity [11] . IS suppressed EPO receptor Akt signaling pathway in extra-hematopoietic cells leading to EPO resistance [12] . Results of hierarchical interaction indicated that hemoglobin levels were more likely to be associated F I G U R E 3 : Percentage of patients achieving hemoglobin level >11 g/dL at ending of Period 1 in both treatment arms. Intention to treat analysis showed that 12 patients (46.2%) of add-on AST-120 group (black bar) and four patients (16%) of control group (white bar) reached target hemoglobin levels (P = 0.034). The number of patients reaching target were 11 (57.9%) and 2 (9.5%) in the add-on AST-120 group and control group (P = 0.002), respectively, in per protocol population.
F I G U R E 4 :
Monthly dose of CERA in per protocol patients. Overall, the monthly dose of CERA was 63.12 ± 31.41 μg in add-on AST-120 group (black bar) and 69.17 ± 42.56 μg in control group (P = 0.333, white bar). The dose was 65.35 ± 30.71 μg in add-on AST-120 group and 46.49 ± 42.79 μg in control group (P = 0.003), respectively, for sequence AB patients. The dose was 61.11 ± 32.63 μg in add-on AST-120 group and 89.69 ± 30.61 μg in control group (P < 0.001), respectively, for sequence BA patients.
with eGFR levels rather than serum IS/PCS values. Erythropoiesis is a dynamic process involving multistep erythroid lineage differentiation. A tentative explanation is that by attenuating reactive oxygen species production [14, 18] , AST-120, may in part, interfere with the impaired heme and globulin synthesis of the uremic milieu. Furthermore, by the lowering of IS and improvement of renal function, AST-120 may have helped in preserving more renal EPO-producing cell, enhancing EPO activity and ameliorating EPO resistance. Taken together, the in vitro, in vivo and clinical evidence, suggest that the improvement of renal function and reduction of uremic toxins by AST-120 as an adjuvant to ESA in late-stage CKD patients may result in greater improvement of hemoglobin levels. The exact mechanistic pathway for this phenomenon remains to be elucidated.
The administration of AST-120 may improve renal function. AST-120 inhibits mitochondria production of reactive oxygen species, reduces the interstitial expression of transforming growth factor beta-1 and tissue inhibitor of metalloproteinases-1, ameliorates epithelial-to-mesenchymal transition and reduces interstitial fibrosis in CKD rats [14, 19, 20] . The change in renal function following AST-120 administration has been controversial in randomized controlled clinical trials. In Asian CKD patients, 6 g of AST-120 resulted in a significant reduction of the rate of renal decline (defined by change of eGFR or slope of 1/Cr) but no difference in the proportion of patients progressing to major events (ESRD, death or Scr > 6 mg/dL) as compared with the conventional treatment group [21] [22] [23] . However, 9 g of AST-120 had no impact on renal outcome of Caucasian patients with CKD [13, 24] . Our findings indicate a significant improvement of renal function in the patients who took AST-120, instead of the renal progression in the control group. The serum concentration of IS and PCS were quite different between Asian and Caucasian patients at similar renal function levels [10, 25, 26] . Other discrepancies in the effect of AST-120 on renal function between these study populations may stem from the difference in genetic predispositions, comorbidities, colonic flora, dietary habit or bowel transit and the duration of treatment. Demonstration of change in fecal concentration of uremic toxins may provide further information on the exact clearance of these toxins following use of AST-120 in CKD patients. All this evidence confirms the renoprotective effect of AST-120 in Asian CKD patients; however, this novel therapeutic strategy remains to be proven in a large-scale Caucasian cohort. 
O R I G I N A L A R T I C L E
Although this pilot study suggested a role for AST-120 in improving renal function and serum hemoglobin levels and in predialysis CKD patients, there were limitations of generalizability due to different ethnic groups, the single-center experiences and short observation times. Serum EPO concentrations were not checked because of the exogenous administration of CERA in our patients. We used the change in Scr or eGFR to determine the renal outcome between groups rather than the event-outcome of ESRD or death due to possible small event numbers resulting from the short observation time. The 4-week washout time may cause misinterpretation of possible carryover effect of long-acting ESA in improving hemoglobin levels between periods. However, CERA has been continued during washout period according to hemoglobin levels in both arms of treatment. Furthermore, the statistical results on the carryover effect strengthened the conjecture of our supposition. We proposed several possible explanations to the discrepancy of dose of CERA between treatment periods. First, all participants were ESA-naïve patients. The baseline hemoglobin values of first period of each sequence were the lowest during the study and consequently have to need more CERA dose to achieve target hemoglobin of 12 g/dL. Second, the hemoglobin values increased with repeated dose of CERA of first period, and even during washout period in some cases. Dose of Period 2 have to interrupt to prevent overshooting of hemoglobin if take into account patient safety with large dose of CERA. Finally, the monthly dose of CERA did not differ between two treatment modes and during wash out period in all patients (Figure 3) . The relative reduction of dose of CERA in both Period 2 was similar (a decrease of 28.9% of dose of CERA was observed in Period 2 of sequence AB and 31.8% in Period 2 of sequence BA, respectively). Taken all together, the lower dose of CERA observed in Period 2 of both sequence was reasonable and may have no influence in study end points. Some patients were found to decline participating or withdrawal from the study. However, both intentions to treat and per protocol analyses yielded similar results on the study end points (Figures 2 and 3) . On a par with Japanese studies, we provided 6 g of AST-120 to the treatment group for better tolerability. Further study is required to determine if an increased dose of up to 9 g of AST-120 will result in a better clinical outcome.
In conclusion, this crossover, randomized, fixed dose, controlled study found that adjuvant AST-120 was associated with improved renal function and hemoglobin level and than use of ESA alone in late-stage CKD patients. Increase of eGFR might play intermediate role between serum IS/PCS and improved hemoglobin levels following AST-120 administration. The results confirmed and extended previous experimental observations. These findings chart a new horizon for the treatment of anemia in CKD patients, especially those who require excessive high-dose of ESA to achieve their target hemoglobin levels. Further long-term scale trial is needed to confirm the exact role of AST-120 on the treatment of anemia of renal patients. 
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